Hansa Biopharma: Increase of the number of shares and votes
Lund, Sweden, October 31, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the number of outstanding votes in Hansa have increased during the month of October 2022 as a result of the conversion of a total of 7,733 class C shares to a total of 7,733 ordinary shares. The conversion was carried out by Hansa in order to deliver ordinary shares to participants in Hansa’s incentive program adopted at the annual general meeting in 2019. The total number of votes in Hansa has therefore increased